Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonacog beta pegol in Chinese patients with haemophilia B
2021-004947-25Phase 3
- Sponsor
- Novo Nordisk
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nonacog beta pegol in hemophilia B (HB), sponsored by Novo Nordisk. Primary endpoint: Primary haemostatic effect.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2021-004947-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004947-25.